Product Description
Arzoxifene is a synthetic, aromatic derivative with anti-estrogenic properties. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Arzoxifene)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Endometrial Cancer|Ovarian Cancer|Breast Cancer
Phase 3: Osteoporosis|Osteoporosis, Postmenopausal|Breast Cancer
Phase 2: Breast Cancer|Osteoporosis|Ovarian Cancer|Peritoneal Cancer|Endometrial Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GJAD | P3 |
Completed |
Osteoporosis |
2009-11-30 |
|
| H4Z-MC-GJAV | P2 |
Completed |
Osteoporosis |
2009-10-01 |
|
| H4Z-MC-GJAD | P3 |
Completed |
Osteoporosis, Postmenopausal |
2009-06-01 |
|
| H4Z-MC-GJAR | P3 |
Completed |
Osteoporosis, Postmenopausal |
2008-07-01 |